Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01)
NCT 05735080 Brief Summary Incyclix Bio (Incyclix) is developing INX-315 as an…
Read more arrow_forwardNCT 05735080 Brief Summary Incyclix Bio (Incyclix) is developing INX-315 as an…
Read more arrow_forwardACTRN 12623000959673 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardNCT 06092580 Brief Summary The aims of this clinical trial are (1)…
Read more arrow_forwardACTRN 12623001126606 Brief Summary This study aims to assess the safety and…
Read more arrow_forwardNCT 05544552 Brief Summary The purpose of this study is to…
Read more arrow_forwardACTRN 12620000767909 Brief Summary This is a substudy of the Cancer Molecular…
Read more arrow_forwardNCT 05267626 Brief Summary This is a first in human, open-label, multi-center…
Read more arrow_forwardNCT 06819735 Brief Summary This is a phase 1/2, dose-escalation and cohort-expansion…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this study…
Read more arrow_forwardNCT 06003621 Brief Summary This phase II study will explore the effect…
Read more arrow_forward